Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.
John Mendelson, Jeremy Coyle, Juan Carlos Lopez, Matthew J. Baggott, Keith Flower, E Thomas Everhart, Thomas A Munro, Gantt P. Galloway, Bruce M Cohen
Psychopharmacology April 1, 2011 DOI: 10.1007/s00213-010-2103-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Placebo-controlled ascending-dose design Peer reviewed |
|---|---|
| Sample size | 8 |
| Population | Salvia divinorum-experienced subjects |
| Intervention | Salvinorin A |
| Dose | up to 4 mg |
| Topics | Salvia divinorum |
| Keywords | Bioavailability Sublingual administration Pharmacology |
| Citations | 40 |
| Key points | Sublingual salvinorin A at doses up to 4 mg produced no greater physiological or subjective effects than placebo and had low bioavailability. |
Abstract
Salvinorin A (SA) is a highly selective kappa opioid receptor agonist and the putative psychoactive compound in Salvia divinorum (SD), an increasingly abused hallucinogenic plant. The objectives of this study were to characterize the physiological and subjective effects of SA versus placebo and measure drug and metabolite levels. Sublingual SA doses up to 4 mg were administered in dimethyl sulfoxide/polyethylene glycol 400 solution to eight SD-experienced subjects using a placebo-controlled ascending-dose design. No dose of SA produced significantly greater physiological or subjective effects than placebo. Furthermore, effects did not resemble reported "typical" effects of smoked SD. SA was detectable in plasma and urine, but was, in most cases, below the reliable limit of quantification (0.5 ng/mL). Our results suggest that the sublingual bioavailability of SA is low. Higher doses, alternate formulations, or alternate routes of administration will be necessary to study the effects of SA in humans.
Comparable studies
Other randomized controlled trials on salvia divinorum, most cited first.
Citations in the library
Cited by 18
- Clinical applications of hallucinogens: A review. Experimental and Clinical Psychopharmacology August 1, 2016
- Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology March 1, 2013
- Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biological Psychiatry November 15, 2012
- Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacological Reviews June 1, 2011
- Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders Frontiers in Pharmacology September 8, 2015
and 13 more in the library
Cites 19
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
- The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans Pharmacopsychiatry July 1, 1998
- Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum(Labiatae) Journal of the Chemical Society Perkin Transactions 1 1982
- Divinorin A, a psychotropic terpenoid, and divinorin B from the hallucinogenic Mexican mint, Salvia divinorum The Journal of Organic Chemistry November 1, 1984
- Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). Journal of Ethnopharmacology May 1, 1983
and 14 more in the library